18.01.2021 • NewsAzelis

Azelis Enters Philippines with APKI and PSSI Buys

Azelis has agreed to buy majority shareholdings in Asia Primera Kimika Inc. (APKI) and Phil-Asiatic Supply & Services Inc. (PSSI), entering the Philippine market and significantly strengthening its footprint in Southeast Asia.

The transaction is expected to close within the next three months. Financial terms were not revealed.

Commenting on the acquisition, Terry Del Rosario, managing director of both APKI and PSSI, said: “Azelis and APKI and PSSI have highly complementary business models which will help us diversify our product portfolio significantly. We will leverage Azelis’ strong focus on the food industry in Asia Pacific which will help us expand our presence in this market.”

Azelis said that the Philippine companies’ strong presence in the personal care segment directly benefits from the population’s increasing purchasing power and growing access to premium products. According to the Luxembourg-headquartered multinational distributor, the Philippines has a population of more than 100 million, a rapidly growing economy and a young workforce with a median age of 26 years. The World Bank is forecasting GDP growth in the Philippines of 5.9% in 2021 and 6% in 2022.

This latest move is the third acquisition that Azelis has announced in a little over three weeks. Earlier this month, it said it was buying major stakes in Vietnamese firms MKVN Chemicals and Viet Chemicals Trading and Service, which was preceded in December by an agreement to purchase CW Pacific in Australia.

Author: Elaine Burridge, Freelance Journalist

Azelis is to buy majority shareholdings in Asia Primera Kimika Inc. (APKI) and...
Azelis is to buy majority shareholdings in Asia Primera Kimika Inc. (APKI) and Phil-Asiatic Supply & Services Inc. (PSSI), entering the Philippine market and significantly strengthening its footprint in Southeast Asia. The deal is expected to close within the next three months. (c) Azelis

Company

Logo:

Azelis Corporate Services NV

12 box 6, Posthofbrug
2600 Antwerpen
Belgium

Company contact







Free Virtual Event

Vaccine Manufacturing
Bioprocess Forum

Vaccine Manufacturing

Join global experts and innovators for a two-day virtual event exploring the latest breakthroughs and best practices in vaccine manufacturing. Discover how new technologies and process innovations are shaping the future of vaccine production, safety, and scalability.

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.

most read

Photo
21.03.2025 • News

What’s Next for Pharma Supply Chains?

Sudden shifts in demand, supply shortages and global collapse have put immense pressure on pharmaceutical logistics. To address these challenges, PHARMAP 2025 brings together industry experts to discover AI-driven supply chain optimisation, strategic logistics partnerships and digital solutions that enhance efficiency and resilience in the pharmaceutical supply chain.

Photo
24.04.2025 • NewsBioprocessing

Fujifilm Diosynth Biotechnologies & Regeneron Sign Manufacturing Agreement

Fujifilm Diosynth Biotechnologies, a contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, today announced a 10-year manufacturing supply agreement, valued at over $3 billion (€2.64 billion), with Regeneron Pharmaceuticals to provide US-based production of its industry-leading biologic medicines, which treat millions of patients worldwide.

Photo
27.03.2025 • News

J&J to Invest $55 Billion in US Operations

US healthcare giant Johnson & Johnson (J&J) has unveiled plans to invest over $55 billion in the US over the next four years. This significant investment marks a 25% increase compared to the previous four years, the company said.